Immunology Data Shows INOVIO's INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of Surgeries for RRP Patients Observed in Phase 1/2 Trial
Go back to Immunology Data Shows INOVIO's INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of Surgeries for RRP Patients Observed in Phase 1/2 Trial| INOVIO PHARMACEUTICALS, Inc. (NASDAQ: INO) | Delayed: 1.21 +0.06 (5.22%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.15 | 52 Week High | $11.69 | |||
| Open | $1.15 | 52 Week Low | $4.50 | |||
| Day High | $1.25 | P/E | N/A | |||
| Day Low | $1.15 | EPS | $-0.28 | |||
| Volume | 2,724,071 | |||||
